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Research
According to the U.S. Environmental 
Protection Agency (EPA), an endocrine dis­
ruptor is “an exogenous agent that interferes 
with the synthesis, secretion, transport, bind­
ing, action, or elimination of natural hor­
mones in the body that are responsible for the 
maintenance of homeo  stasis, reproduction, 
development and/or behavior” (Kavlock et al. 
1996). Bisphenol A (BPA), one of these com­
pounds, is one of the highest volume chemi­
cals produced worldwide, with > 6 billion 
pounds produced each year. BPA is a con­
stituent of poly  carbonate plastics and epoxy 
resins used in the food industry and in den­
tistry. The polymer bonds hydrolyze at high 
tempera  tures and release BPA. BPA can be 
ingested by humans; detectable amounts of 
BPA have been found in food cans, micro­
wave containers, human saliva after treatment 
with dental sealants, and polycarbonate bottles 
(Vandenberg et al. 2007). More elevated levels 
of BPA have been found in neonates and chil­
dren. Infants can be exposed to BPA through 
different sources; as noted by Vandenberg 
et al. (2007), detectable levels of BPA in breast 
milk (0.28–0.97 ng/mL and 1.1 ng/mL) have 
been reported in two different studies, as well 
as in human colostrum (1–7 ng/mL) and in 
polycarbonate baby bottles. BPA has also been 
found in medical devices (Calafat et al. 2009). 
Edginton and Ritter (2009) estimated the 
daily exposure for newborns and children at 
3 and 6 months of age, under different feed­
ing scenarios, finding exposures that ranged 
from 0.25 µg/kg/day in breast­fed newborns 
to 8.3–13 µg/kg/day in 6­month­old infants 
fed commercial formula or other beverages 
using poly  carbonate bottles.
Although in vitro assays have suggested 
that BPA is a weak environmental estrogen, 
it has also been shown to antagonize the 
effects of estrogens, androgens, and thyroid 
hormones; act through non  genomic path­
ways; and influence enzyme activity or recep­
tor expression (Wetherill et al. 2007). In vivo 
effects also have been reported based on stud­
ies using a wide range of doses, animal mod­
els, and end points. The current U.S. EPA 
reference dose for BPA (50 µg/kg/day) was 
calculated by dividing the lowest observed 
adverse effect level (LOAEL; 50 mg/kg/day) 
by 1,000 (Diamanti­Kandarakis et al. 2009). 
In some studies, low doses are considered 
those less than the LOAEL. Effects of BPA 
can be influenced by species, strain, dose, and 
time of exposure, and adult animals exposed 
to BPA show effects that are reversible when 
the exposure ceases (Richter et al. 2007). In 
contrast, perinatal/neonatal exposures pro­
duce “organizational” effects [effects resulting 
from exposure during organ development 
and continuing through puberty that may 
result in persistent alterations of the affected 
systems (Richter et al. 2007)] in different 
strains of rats (Adewale et al. 2009; Durando 
et al. 2007; Fernández et al. 2009; Kato et al. 
2003; Khurana et al. 2000; Moral et al. 2008; 
Patisaul et al. 2006; Ramos et al. 2003; Rubin 
et al. 2001).
Gonadotropin­releasing hormone (GnRH) 
is a hypothalamic deca  peptide critical for 
normal mammalian reproduction. It acts on 
gonadotropes to stimulate synthesis and release 
of luteinizing hormone (LH) and follicle­ 
stimulating hormone (FSH) (Pawson and 
McNeilly 2005). GnRH secretion is pulsa  tile, 
and its frequency varies over the female men­
strual cycle and during development. Increases 
in plasma gonadotropins follow the GnRH 
peaks, and disruption in the normal pulsa­
tile secretion causes reproductive dis  orders in 
humans, such as polycystic ovarian syndrome 
(PCOS) (Marshall et al. 2001). PCOS is con­
sidered the most common endocrine abnor­
mality in reproductive­age females—occurring 
in 4–8% of women—and is characterized by 
elevated serum LH, testosterone, and insulin; 
low or normal levels of FSH; abnormalities of 
estrogen secretion; and premature pubic hair 
growth (pubarche). There is hetero  geneity in 
these alterations among women with poly­
cystic ovaries, and in some individuals these 
characteristics may change over time. Women 
with PCOS are at increased risk of develop­
ing insulin resistance, diabetes, endometrial 
cancer, and anovulatory infertility. Thus, this 
syndrome is charac  terized by metabolic and 
reproductive disorders (Marshall et al. 2001).
Previously, we have shown that neo  natal 
BPA exposure alters pituitary function in 
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Ba c k g r o u n d: Bisphenol A (BPA), an endocrine disruptor, is a component of polycarbonate 
plastics, epoxy resins, and polystyrene. Several studies have reported potent in vivo effects, because 
BPA behaves as an estrogen agonist and/or antagonist and as an androgen and thyroid hormone 
antagonist.
oBjectives: We investigated the effects of neonatal exposure to BPA on the reproductive axis in 
adult female Sprague-Dawley rats.
Me t h o d s : Female rats were injected subcutaneously, daily from postnatal day 1 (PND1) to 
PND10 with BPA in castor oil at 500 µg/50 µL [BPA500; ~ 10–4 M, a dose higher than the lowest 
observed adverse effect level (LOAEL) of 50 mg/kg], 50 µg/50 µL (BPA50), or 5 µg/50 µL (both 
BPA50 and BPA5 are doses lower than the LOAEL), or castor oil vehicle alone. In adults we studied 
a) the release of gonadotropin-releasing hormone (GnRH) from hypothalamic explants, b) serum 
sex hormone levels, and c) ovarian morphology, ovulation, and fertility.
re s u l t s: Neonatal exposure to BPA was associated with increased serum testosterone and estradiol 
levels, reduced progesterone in adulthood, and altered in vitro GnRH secretion. Animals exposed 
to BPA500 had altered ovarian morphology, showing a large number of cysts. Animals exposed to 
BPA50 had reduced fertility without changes in the number of oocytes on the morning of estrus, 
whereas animals exposed to BPA500 showed infertility.
co n c l u s i o n s: Exposure to high doses of BPA during the period of brain sexual differentiation 
altered the hypothalamic–pituitary–gonadal axis in female Sprague-Dawley rats. These results have 
the potential to link neonatal exposure to high doses of BPA in rats with the develop  ment of poly-
cystic ovarian syndrome. Studies of doses and routes of administration more consistent with human 
exposures are needed to determine the relevance of these findings to human health.
key w o r d s : bisphenol A, GnRH pulsatility, ovary, PCOS, sex hormones. Environ Health Perspect 
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postnatal day 13 (PND13) and adult female 
rats, both in vitro and in vivo (Fernández et al. 
2009). In the present study we continued to 
explore the effects of neonatal exposure to BPA 
on other reproductive parameters in female 
Sprague­Dawley rats. We analyzed GnRH 
release from hypothalamic explants, sex hor­
mone levels in serum, ovarian morphology, 
ovulation, and fertility.
Materials and Methods
Animals. Studies were performed according 
to protocols for animal use, approved by the 
Institutional Animal Care and Use Committee 
[IByME­CONICET (Instituto de Biología 
y Medicina Experimental, Consejo Nacional 
de Investigaciones Científicas y Técnicas]. 
Animals were treated humanely and with 
regard for alleviation of suffering.
Sprague­Dawley rats (200–250 g body 
weight) from the IByME colony, established 
from Charles River stock in 1985, were main­
tained under a controlled 12­hr light/dark 
cycle and temperature conditions. They were 
housed in steel cages with wood shavings as 
bedding material and given free access to com­
mercial laboratory chow (Gepsa Feeds, Grupo 
Pilar S.A, Córdoba, Argentina) and tap water 
in glass bottles. Phyto  estrogen concentration 
in the food was not tested, but we assumed 
that all animals were exposed to the same lev­
els, because food intake was equivalent among 
groups (Fernandez MO, Bourguignon NS,   
Lux­Lantos VAR, Libertun C, unpublished 
data). In our experiments, phyto  estrogens 
were constant in the diet and BPA was tested 
at different doses, so we cannot exclude the 
possibility of some inter  action between BPA 
and phyto  estrogens (Charles et al. 2007).
Pregnant females were housed singly,   
and on the day of birth (PND1), pups in 
each litter were reduced to eight. From 
PND1 to PND10, female pups received 
daily subcutaneous (SC) injections of BPA 
(Aldrich, Milwaukee, WI, USA) in castor 
oil, as previously described (Fernández et al. 
2009): 50 µg/50 µL (BPA50; dose range,   
6.2–2.5 mg/kg), 500 µg/50 µL (BPA500; dose 
range, 62.5–25.0 mg/kg), 5 µg/50 µL (BPA5; 
dose range, 0.62–0.25 mg/kg), or castor oil 
vehicle alone (control). Each litter included 
one female pup in each exposure group, so that 
a given litter included one control, one BPA5, 
one BPA50, and one BPA500; this allowed us 
to control for possible effects due to dam vari­
ability. The four remaining pups in each lit­
ter were untreated males; they were kept until 
weaning but were not used for this study. 
The highest BPA dose used in this study 
(500 µg/µL) has been used by others in this 
and other strains of rats (Khurana et al. 2000; 
Patisaul et al. 2006, 2007); because it is above 
the LOAEL, we consider it “high dose.” The 
50 µg/50 µL and 5 µg/50 µL doses were below 
the LOAEL and are therefore referred to as 
“low doses.” Although the SC route is not a 
typical route of exposure in humans (Richter 
et al. 2007), we chose it based on a report 
from Taylor et al. (2008) that showed that 
during the neonatal period, oral and non  oral 
administration of BPA give the same internal 
active dose in rodents because of the low liver 
enzyme activity in neonatal rodents.
We previously determined that adult 
BPA500 animals had irregular estrous cycles, 
with high prevalence of estrus (Fernández 
et al. 2009); therefore, studies were performed 
with all animals in estrus, determined by vagi­
nal smears. For all these studies, animals were 
used at 4–5 months of age.
Serum sex hormone levels. Serum estradiol, 
testosterone, and progesterone were deter­
mined in trunk blood by radio  immunoassay 
(RIA) as previously described (Bianchi et al. 
2004; Silveyra et al. 2007), using specific 
anti  sera kindly provided by G.D. Niswender 
(Colorado State University, Fort Collins, CO, 
USA) after ethyl ether extraction. Labeled 
estradiol and progesterone were obtained from 
Perkin­Elmer (Wellesley, MA, USA), and tes­
tosterone was from New England Nuclear 
(Boston, MA, USA). Assay sensitivities were 
11.3 pg (estradiol), 12.5 pg (testosterone), 
and 500 pg (progesterone). Intra­ and inter­
assay coefficients of variation were 6.8% and 
11.7% for estradiol, 7.1% and 12.15% for 
progesterone, and 7.8% and 12.3% for testos­
terone, respectively.
GnRH release from hypothalamic 
explants. Studies were performed in vitro as 
described previously (Fernández et al. 2009). 
One hypothalamic explant from each animal 
group (control, BPA50, BPA500) was used 
for each experiment. After 30 min of pre­
incubation, the medium from each flask was 
renewed at 9­min intervals for 6 hr and stored 
at –20°C for GnRH measurement (RIA).
GnRH pulses were identified and inter­
pulse intervals (IPIs) determined by Cluster8 
analy  sis (Veldhuis and Johnson 1986) using 
Pulse_XP software (http://mljohnson.pharm.
virginia.edu/home.html). We used a 2 × 2 
cluster configuration and a t­statistic of 2 for 
the upstroke and downstroke to maintain 
false­positive and false­negative error rates 
< 10% (Martinez de la Escalera et al. 1992). 
The experiment was repeated six times, with 
animals from BPA500, BPA50, and control 
groups in each experiment (total of 6 hypo­
thalami/group). 
Ovarian morphology. To evaluate changes 
in the ovarian structure, we collected ovaries 
from rats in each group (control, BPA50, and 
BPA500). Some of the ovaries were randomly 
selected for weighing after laparotomy, and 
others were immediately fixed in 5% neutral 
buffered formaldehyde for histological exami­
nation. Sections cut from paraffin­embedded 
ovaries were stained with hematoxylin and 
eosin to count pre  ovulatory follicles, corpora 
lutea, antral follicles, and atretic follicles using 
a light microscope as described by Parborell 
et al. (2005).
Ovulation and fertility. On the morning 
of estrus, ovaries were removed from seven 
animals in each treatment group, and ovula­
tion was evaluated by microscopic examina­
tion of the oviducts (Silveyra et al. 2007). To 
determine fertility, we placed female rats from 
each experimental group with a male of known 
fertility (one female from each treatment: con­
trol, BPA5, BPA50, and BPA500, four in total, 
with one male). When females were deter­
mined to be pregnant, they were separated and 
Figure 1. Neonatal exposure to BPA alters sex hormone levels in serum of adult female rats. (A) Serum estradiol (n = 7). (B) Serum testosterone (n = 9). (C) Serum 
progesterone (n = 9). 
*p < 0.05 compared with control, and #p < 0.05 compared with BPA5, as determined by ANOVA.
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housed individually. We counted the number 
of pups on the day of birth (PND1). 
Statistical analysis. Results are expressed 
as mean ± SE, and values are considered 
significant at p < 0.05. Data were analyzed 
by one­way analysis of variance (ANOVA) 
(Statistica, version 5; Statsoft Inc., Tulsa, OK, 
USA) with a Student­Newman­Keuls posttest 
and transformed when the test for homo­
geneity of variances so required.
Results
Sex hormone levels and GnRH IPIs in adult 
female rats. We first determined sex hormone 
serum levels in BPA­treated animals. Adult 
BPA500 and BPA50 animals had higher lev­
els of testosterone and estradiol, and all BPA 
groups showed lower levels of progesterone 
than controls, although BPA500 was the most 
affected group (Figure 1).
Researchers have shown that alterations in 
sex hormone levels could modify GnRH/LH 
pulsatility (Marshall et al. 2001). We therefore 
measured this parameter in vitro in BPA50 and 
BPA500 hypothalami, because these were the 
treatment groups in which more alterations 
had been observed. Adult female rats neonatally 
exposed to BPA presented alterations in GnRH 
secretion, as demonstrated by a decrease in the 
IPI (Figure 2A), in agreement with results from 
our previous study (Fernández et al. 2009). 
Representative patterns of GnRH secretion are 
shown in Figure 2B–D.
Morphological alterations in the ovary. 
Alterations in sex hormone levels and GnRH 
pulsatility could be consistent with altera­
tions at the ovarian level, so we studied some 
ovarian parameters in control, BPA50, and 
BPA500 animals, because these two BPA­
exposed groups revealed alterations in GnRH 
IPI. Macroscopic observation showed that 
ovaries from the BPA­exposed animals were 
smaller than those from controls, as con­
firmed by ovarian weight (Figure 3); there 
were no differences in body weight.
Histological analysis of the ovaries demon­
strated a large number of cysts in BPA500 
animals, which were comparable with high­
dose animals reported in other animal mod­
els of PCOS (Sotomayor­Zárate et al. 2008). 
We also determined the number of corpora 
lutea, antral follicles, atretic follicles, and pre­
ovulatory follicles in each group. As shown in 
Figure 4A, adult animals neonatally exposed 
to BPA500 showed a lower number of corpora 
lutea and a higher number of atretic follicles, 
many of which were cystic. We define “cystic 
follicles” as anovulatory follicles with a thin 
granulosa layer (two to three layers) and non­
detectable theca (Figure 4E,F). Both BPA­
treated groups showed lower numbers of antral 
follicles. As shown in Figure 4B, BPA500 ani­
mals had a lower total number of structures, in 
agreement with the decrease in ovarian weight. 
Figure 4C–F shows representative sections 
from each group.
Alterations in fertility. We also investi­
gated whether neonatal exposure to BPA 
impaired ovulation and/or fertility. In controls 
and all BPA­exposed groups, we counted the 
number of oocytes in the ampulla of the ovi­
duct on the morning of estrus, and the num­
ber of pups delivered after being mated with a 
male of known fertility. BPA500 animals did 
not ovulate or deliver any pups. BPA50 and 
BPA5 animals presented the same number 
of oocytes as controls (Figure 5A). In fertil­
ity studies, BPA5 animals delivered the same 
number of pups as controls, whereas BPA50 
animals delivered significantly fewer pups, 
indicating subfertility (Figure 5B).
Discussion
We previously showed that neonatal exposure 
to BPA had profound effects on the organiza­
tion of the hypothalamic–pituitary unit in 
female rats (Fernández et al. 2009). In the 
present study, we were interested in deter­
mining whether exposure to BPA during the 
neonatal period (which is important for brain 
sexual differentiation) had other effects on the 
reproductive axis.
We found that exposure to 500 and 
50 µg/day BPA accelerated GnRH pulse fre­
quency in hypothalamic explants from adult 
rats. We previously reported that this expo­
sure increased the number of GnRH peaks 
per hour (Fernández et al. 2009), and here we 
quantify this according to the length of the 
IPI, which is reduced. Many endocrine disor­
ders are associated with alterations in GnRH 
pulsatility, and a very common disorder found 
in adult women, PCOS, is charac  terized by 
an increase in GnRH/LH pulse frequency 
and elevated LH/FSH index. An increase in 
GnRH/LH pulsatility could be a cause and/or   
consequence of alterations in sex hormone 
levels. In our model, we found elevated levels 
of serum estradiol and testosterone, and a 
decrease in progesterone. We hypothesize that 
the elevation in testosterone is driven by the 
increase in GnRH/LH pulse frequency, as 
has been reported in PCOS (Marshall et al. 
2001). However, the reduction in progester­
one could be causing the altered GnRH pul­
satility, because progesterone is a well­known 
regu  lator of GnRH pulse frequency (Marshall 
et al. 2001). A decrease in serum levels of 
progesterone is another feature present in 
PCOS (Marshall et al. 2001). Interestingly, 
Takeuchi et al. (2004) found that serum BPA 
concentrations were higher in a small sam­
ple of women with PCOS. However, some 
researchers have speculated that elevated BPA 
is a consequence, and not a cause, of PCOS 
(Crain et al. 2008), because women with 
PCOS have higher circulating testosterone 
levels than do healthy women, and elevated 
Figure 2. Neonatal exposure to BPA diminishes 
GnRH IPI in adult female rats, as determined by 
GnRH release from hypothalamic explants in vitro 
(n = 6 per treatment). (A) GnRH IPI. Representative 
pulsatility patterns of control (B), BPA50 (C), and 
BPA500 (D) treatment.
*p < 0.05 compared with control, as determined by ANOVA.
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Figure 3. Neonatal exposure to BPA alters ovarian 
weight without changing body weight in adult rats. 
(A) Ovarian weight. (B) Body weight of the same 
animals.
*p < 0.05 compared with control, **p < 0.005 compared with 
control, and #p < 0.05 compared with BPA50, as determined 
by ANOVA (n = 6 per treatment).
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androgen concentrations decrease BPA clear­
ance (Diamanti­Kandarakis et al. 2009).
Because animals in the BPA500 and 
BPA50 groups showed extensive hormonal 
alteration in the gonadotropic axis, we next 
focused our attention on the ovary. Ovaries 
from animals neonatally exposed to BPA (50 or 
500 µg/day) were smaller than those from con­
trols, and ovaries from BPA500­treated ani­
mals were smaller than those from animals 
treated with BPA50. In addition, ovaries from 
BPA500 animals had fewer corpora lutea,   
fewer antral follicles, and more atretic follicles 
than did those from controls. In fact, many 
of the atretic follicles were cystic, and these 
cysts were very similar to those found in ani­
mal models of PCOS (Sotomayor­Zárate et al. 
2008). BPA50 animals also had fewer antral 
follicles, but they did not show the profound 
alterations observed in high­dose animals. The 
alterations might be due to direct actions of 
BPA in the ovary or to indirect effects resulting 
from alterations in the hypothalamic–pituitary 
unit, or a combination of both.
Sotomayor­Zárate et al. (2008) described 
a decrease in the number of antral follicles 
and corpora lutea in animals neonatally 
exposed to estradiol valerate (EV; 0.1 mg on 
PND1). These authors demonstrated that 
the EV exposure provoked alterations in 
the normal develop  ment of the ovary, lead­
ing to the formation of multi  follicular cysts, 
and they also described alterations to estrus 
cycles. In an earlier study, Kato et al. (2003) 
described cystic follicles in animals exposed 
daily to BPA (1 or 4 mg) from PND1 to 
PND10; they observed an absence of cor­
pora lutea in animals exposed to 4 mg but 
not in animals exposed to 1 mg. In the pres­
ent study, we found ovaries with cysts and 
absence of corpora lutea in animals exposed 
to 500 µg/day, whereas animals exposed to 
50 µg/day presented some less severe altera­
tions. Adewale et al. (2009) found that ani­
mals exposed to BPA from PND0 to PND3 
at a dose of 50 mg/kg body weight per day 
developed ovarian alterations similar to those 
we observed here. However, they did not 
find altered activation of GnRH neurons, 
meas  ured using Fos immuno  staining after 
ovariec  tomy and hormone replacement. One 
difference between the studies is the tech­
nique used to measure activity in GnRH neu­
rons: We measured the frequency of GnRH 
released by the hypothalamus in intact females 
and found alterations in all BPA groups 
tested. Another difference is the duration of 
the exposure; Adewale et al. (2009) treated 
animals for 4 days total, whereas we treated 
animals for 10 days (PND1–PND10). 
So far, the results from the present study 
are the first to link neonatal exposure to high 
doses of BPA with development of PCOS­
like abnormalities in adult  hood. Further stud­
ies are needed to determine if rats neonatally 
exposed to BPA show other features associ­
ated with PCOS, such as insulin resistance, 
obesity, and neuronal and immune system 
alterations (Chapman et al. 2009; Sotomayor­
Zárate et al. 2008). Rubin et al. (2001) found 
that peri  natal exposure to BPA affected body 
weight in adult rats. Other authors have 
reported that long­term treatment of male 
mice with BPA altered the pancreatic content 
and secretion of insulin and resulted in post­
prandial insu  linemia and insulin resistance 
Figure 4. Neonatal exposure to BPA alters ovarian histology in adult female rats. Ovaries from control 
and BPA-treated animals were stained with hematoxylin and eosin and viewed under a light microscope. 
Abbreviations: AF, antral follicles; Atr F, atretic follicles; CL, corpus luteum; GC, granulosa cell; POF, 
preovulatory follicles. (A) Number of ovarian structures by type of structure. (B) Total number of struc-
tures by treatment. (C–F) Representative slides from each treatment. (C) Control. (D) BPA50. (E) BPA500. 
(F) A higher magnification of (E), showing a cystic follicle in detail; the inset shows the thin granulosa layer 
and non  detectable theca in the follicle. 
*p < 0.05 compared with control, by structure type in (A) and by treatment in (B), as determined by ANOVA (n = 5).
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(Alonso­Magdalena et al. 2006). In another 
study, Hugo et al. (2008) found that, in vitro, 
BPA inhibits the release of adipo  nectin (a key 
adipo  kine that protects humans from meta­
bolic syndrome) from human adipose tissue. 
Other groups have reported that in vitro BPA 
affects adipocyte differentiation (Masuno 
et al. 2005) and increases expression of dif­
ferentiation genes (Phrakonkham et al. 2008). 
These results support the hypothesis that peri­
natal exposure to BPA could affect metabolic 
parameters (Rubin and Soto 2009).
Regarding the mechanism by which BPA 
acts to produce the effects seen here, many 
hypotheses can be made. BPA has been shown 
to act through estrogen receptors (ERs) and 
through other mechanisms (Wetherill et al. 
2007). Ovarian alterations observed in the 
present study mimic the results obtained with 
EV by Sotomayor­Zárate et al. (2008). In our 
study, the molar concentrations of BPA admin­
istered ranged between 10–4 M (BPA500) and 
10–5 M (BPA5); the EV concentration used 
by Sotomayor­Zárate et al. (2008) was similar 
to the molar concentration of our medium 
dose (BPA50). According to Heisterkamp et al. 
(2004), who compared the potency of BPA 
and EV with the ERα, the median effective 
concentration (EC50) of BPA is higher than the 
EC50 of EV; therefore, the results of the pres­
ent study and those of Sotomayor­Zárate et al. 
(2008) could suggest that both compounds 
are acting by the same mechanisms. However, 
the specific receptors through which BPA acts 
in the entire animal have been reported to be 
different depending on the tissue in question, 
because it has been shown that for a given cell 
type, the activity of BPA depends on the levels 
of different ER variants expressed (Wetherill 
et al. 2007). We also have to keep in mind 
that the outcomes we are describing are evi­
dent in adulthood and may be the result of an 
accumulation of alterations, rather than being 
outcomes triggered by a unique event.
Children can be exposed to BPA doses rang­
ing from 0.2 µg/kg/day to 8.3–13 µg/kg/day   
(Edginton and Ritter 2009), which would cor­
respond to a single dose of 10–9 M to 10–8 M. 
To calculate children’s exposure levels, we 
assumed exposure to a single dose of BPA 
to an infant whose body weight was 3.5 kg 
(PND5) or 7 kg (6 months old). Because the 
doses we used in the present study are much 
higher than the doses infants may be exposed 
to (~ 10–5 M vs. ~ 10–9 M), further research 
should be performed using doses that are 
more relevant to human exposure. We chose 
the SC route of exposure based on a report 
by Taylor et al. (2008) that shows this route 
is valid in neonates; however, we admit that 
oral adminis  tration would be more rele  vant 
to humans. In addition, some researchers do 
not support the conclusion that injections and 
oral adminis  tration produce similar internal 
exposures (Richter et al. 2007). Also, the 
experimental protocol we used—treating litter­
mates with the different doses—could result in 
cross­contamination and is thus a potential 
limitation of the present study. 
Finally, we studied ovulation and fertil­
ity in adult animals neonatally exposed to 
BPA. We found that animals exposed to 
BPA50 and BPA5 were comparable with 
controls regarding the number of oocytes 
in the oviduct on the first day of estrus, 
whereas BPA500 animals did not ovulate, in 
accordance with our previous observations 
(Fernández et al. 2009). In fertility studies we 
found that BPA50 females delivered a signifi­
cantly smaller number of pups than did con­
trols and that BPA500 animals were infertile. 
Varayoud et al. (2008) reported that neonatal 
exposure to BPA was associated with altered 
gene expression and hormone responsiveness 
in uterine stroma in adulthood, which could 
contribute to impaired fertility. However, 
other effects, such as effects on sex hormone 
levels during pregnancy or oocyte quality, 
could also contribute to reduced fertility. 
Indeed, oocytes are one of the longest lived, 
non  regenerating cells in the body and are 
subject to a lifetime of environmental expo­
sures that are difficult to quantify (Crain et al. 
2008). Further studies are needed to analyze 
effects of exposure to BPA on these param­
eters. For example, it would be interesting 
to treat the affected animals with pregnant 
mare’s serum gonadotropin and human cho­
rionic gonadotropin to determine if the fertil­
ity of these animals can be rescued, or if there 
is also a uterine component underlying the 
infertility.
The results presented here support the 
hypothesis that neonatal exposure to high 
doses of BPA affects the reproductive axis 
in adulthood. We observed these changes 
in animals > 4 months of age, long after the 
exposure to the endocrine disruptor had 
ceased. We suggest that neonatal exposure to 
500 µg BPA (a dose higher than the LOAEL) 
provoked irreversible alterations in the   
hypothalamic–pituitary–gonadal axis that led 
to anovulation and infertility, and that 50 µg 
BPA (a dose lower than the LOAEL) pro­
voked more subtle alterations at the hypotha­
lamic level that could lead to subfertility. The 
effects of lower BPA doses (more rele  vant to 
human exposure) should be studied further. 
The results presented here reinforce the notion 
that many diseases that appear in adulthood 
have their origin during development and 
that alterations in the normal ontogeny may 
result in irreversible “organizational” effects 
[effects that begin during prenatal develop­
ment and continue through puberty, resulting 
in persistent alterations of the affected sys­
tems (Richter et al. 2007)] that may become   
evident only in adults.
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